Download PDF
Nervenheilkunde 2019; 38(05): 240-248
DOI: 10.1055/a-0873-7862
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Morphologische Charakteristika der Muskelbiopsie bei inflammatorischen Myopathien

Anne Schänzer
1   Institut für Neuropathologie, Justus-Liebig-Universität Gießen
,
Hilmar Hans Goebel
2   Institut für Neuropathologie, Charité – Universitätsmedizin Berlin
,
Werner Stenzel
2   Institut für Neuropathologie, Charité – Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
06 May 2019 (online)

    Permissions and Reprints

ZUSAMMENFASSUNG

Die Klassifizierung von immunvermittelten inflammatorischen Myopathien (IIM), häufig meist als Myositis bezeichnet, wurde in den letzten Jahren einem interessanten Wechsel unterzogen. Neben klinischen Befunden haben der Nachweis von Autoantikörpern und eine detaillierte morphologische Analyse der Muskelbiospie die Aussage für die Prognose der Erkrankung und damit die Therapieoption deutlich verbessert. Zum Beispiel gehen verschiedene Subtypen einer Dermatomyositis mit einem unterschiedlichen Risiko einer malignen Grunderkrankung oder einer extramuskulären Beteiligung einher. Daher ist eine genaue Einordnung der Pathologie von Skelettmuskelbiopsien unter Verwendung von Spezialfärbungen hilfreich. In dem folgenden Übersichtsartikel werden die wichtigsten Befunde der verschiedenen morphologischen Subtypen der IIM, insbesondere der Dermatomyositis und immunvermittelten nekrotisierenden Myopathie beschrieben und gegenüber anderen Entitäten abgegrenzt.

 

  • Literatur

  • 1 Allenbach Y, Benveniste O, Goebel HH, Stenzel W. Review: Integrated classification of inflammatory myopathies.. Neuropathol Appl Neurobiol 2017; 43 (01) 62-81.
    CrossrefPubMedGoogle Scholar
  • 2 Mescam-Mancini L, Allenbach Y, Hervier B, Devilliers H, Mariampillay K, Dubourg O. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis.. Brain 2015; 1389 Pt (09) 2485-92.
    Google Scholar
  • 3 Stenzel W, Preusse C, Allenbach Y, Pehl D, Junckerstorff R, Heppner FL. et al Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy.. Neurology 2015; 84 (13) 1346-54.
    CrossrefPubMedGoogle Scholar
  • 4 Aouizerate J, DeAntonio M, Bassez G, Gherardi RK, Berenbaum F, Guillevin L. et al Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy.. Acta Neuropathol Comm 2014; 2: 154.
    Google Scholar
  • 5 Allenbach Y, Leroux G, Suarez-Calvet X, Preusse C, Gallardo E, Hervier B. et al Dermatomyositis with or without Anti-Melanoma differentiation-associated Gene 5 Antibodies: Common Interferon Signature but Distinct NOS2 Expression.. Am J Pathol 2016; 186 (03) 691-700.
    CrossrefPubMedGoogle Scholar
  • 6 Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls.. Presse medicale 2011; 40 4 Pt 2 e249-55.
    CrossrefPubMedGoogle Scholar
  • 7 Stenzel W, Weis J. Update Muskelbiopsiediagnsotik neuromuskulärer.. Erkrankungen Nervenheilkunde 2017; 36: 17-22.
    Google Scholar
  • 8 H. O. Lehrbuch der Nervenkrankheiten für Ärzte und Studierende.. Berlin: S. Karger; 1894
    Google Scholar
  • 9 Bohan A, Peter JB. Polymyositis and dermatomyositis [second of two parts].. N Engl J Med 1975; 292 (08) 403-7.
    CrossrefPubMedGoogle Scholar
  • 10 Bohan A, Peter JB. Polymyositis and dermatomyositis [first of two parts].. N Engl J Med 1975; 292 (07) 344-7.
    CrossrefPubMedGoogle Scholar
  • 11 Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.. Medicine 2005; 84 (04) 231-49.
    Google Scholar
  • 12 Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR. et al 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis 2003, Naarden, The Netherlands.. J Neuromusc Dis 2004; 14 (05) 337-45.
    PubMedGoogle Scholar
  • 13 De Bleecker JL, De Paepe B, Aronica E, de Visser M, Amato A, Benveniste O. et al 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 2014, Naarden, The Netherlands.. J Neuromusc Dis 2015; 25 (03) 268-72.
    Google Scholar
  • 14 Dubowitz V, Sewry C, Oldfords A. Muscle Biopsy: A Practical Approach.. München: Saunders Elsevier; 2013
    Google Scholar
  • 15 Lahoria R, Selcen D, Engel AG. Microvascular alterations and the role of complement in dermatomyositis.. Brain 2016; 139 Pt 7 1891-903.
    CrossrefPubMedGoogle Scholar
  • 16 Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis.. J Rheumatol 2015; 42 (08) 1448-54.
    CrossrefPubMedGoogle Scholar
  • 17 Merlo G, Clapasson A, Cozzani E, Sanna L, Pesce G, Bagnasco M. et al Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.. Arch Dermatol Res 2017; 309 (02) 87-95.
    CrossrefPubMedGoogle Scholar
  • 18 Rider LG, Danko K, Miller FW. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.. Curr Opin Rheumatol 2014; 26 (06) 724-41.
    CrossrefPubMedGoogle Scholar
  • 19 Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M. et al. Anti-TIF1-gamma antibody and cancer-associated myositis: A clinicohistopathologic study.. Neurology 2016; 87 (03) 299-308.
    CrossrefPubMedGoogle Scholar
  • 20 Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB. et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin.. Medicine 2014; 93 (03) 150-7.
    Google Scholar
  • 21 Bergua C, Chiavelli H, Simon JP, Boyer O, Jouen F, Stenzel W. et al. Immune-mediated necrotizing myopathy.. Z Rheumatol 2016; 75 (02) 151-6.
    CrossrefPubMedGoogle Scholar
  • 22 Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M. et al. Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients.. J Rheumatol 2017; 44 (04) 488-92.
    Google Scholar
  • 23 Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features.. Neurology 1998; 50 (03) 764-7.
    CrossrefPubMedGoogle Scholar
  • 24 Uruha A, Suzuki S, Suzuki N, Nishino I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1.. Brain 2016; 139 pt (09) e50
    CrossrefPubMedGoogle Scholar
  • 25 Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres.. J Neurol Neurosurg Psychiatry 2000; 68 (04) 472-8.
    CrossrefPubMedGoogle Scholar
  • 26 Allenbach Y, Hervier B, Stenzel W, Benveniste O. Reply: Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1.. Brain 2016; 139 pt (09) e51
    CrossrefPubMedGoogle Scholar
  • 27 van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE. et al. Polymyositis: an overdiagnosed entity.. Neurology 2003; 61 (03) 316-21.
    CrossrefPubMedGoogle Scholar
  • 28 Bronner IM, van der Meulen MF, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE. et al. Long-term outcome in polymyositis and dermatomyositis.. Ann Rheum Dis 2006; 65 (11) 1456-61.
    CrossrefPubMedGoogle Scholar
  • 29 Bronner IM, Linssen WH, van der Meulen MF, Hoogendijk JE, de Visser M. Polymyositis: an ongoing discussion about a disease entity.. Arch Neurol 2004; 61 (01) 132-5.
    CrossrefPubMedGoogle Scholar
  • 30 Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F. et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.. JAMA Neurol 2018; 75 (12) 1528-37.
    CrossrefPubMedGoogle Scholar
  • 31 Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.. Neurology 2008; 70 (06) 418-24.
    CrossrefPubMedGoogle Scholar
  • 32 Vilela VS, Prieto-Gonzalez S, Milisenda JC, Selva OCA, Grau JM. Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up.. Rheumatol Int 2015; 35 (05) 915-20.
    CrossrefPubMedGoogle Scholar
  • 33 Albayda J, Mammen AL. Is statin-induced myositis part of the polymyositis disease spectrum?.. Curr Rheumatol Rep 2014; 16 (08) 433.
    CrossrefPubMedGoogle Scholar
  • 34 Dobloug C, Garen T, Bitter H, Stjarne J, Stenseth G, Grovle L. et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort.. Ann Rheum Dis 2015; 74 (08) 1551-6.
    PubMedGoogle Scholar
  • 35 Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, Van Engelen BG. Amyloid deposits and inflammatory infiltrates infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.. Acta Neuropathol 2015; 129 (05) 611-24.
    CrossrefPubMedGoogle Scholar
  • 36 Greenberg SA. Inclusion Body Myositis.. Continuum 2016; 22 (06) 1871-88.
    Google Scholar
  • 37 Schmidt J, Dalakas MC. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives.. Expert Rev Clin Immunol 2013; 9 (11) 1125-33.
    CrossrefPubMedGoogle Scholar
  • 38 Zschuntzsch J, Voss J, Creus K, Sehmisch S, Raju R, Dalakas MC. et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and beta-amyloid in the muscle.. Arthritis Rheum 2012; 64 (12) 4094-103.
    CrossrefPubMedGoogle Scholar
  • 39 Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis.. Neurology 2014; 83 (05) 426-33.
    CrossrefPubMedGoogle Scholar
  • 40 Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.. Hum Pathol 1989; 20 (03) 224-31.
    CrossrefPubMedGoogle Scholar
  • 41 Weihl CC, Mammen AL. Sporadic Inclusion Body Myositis: A myodegenerative disease or an inflammatory myopathy.. Neuropathol Appl Neurobiol 2017; 43 (01) 82-91.
    CrossrefPubMedGoogle Scholar
  • 42 Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N. et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.. J Neurol Neurosurg Psychiatry 2016; 87 (04) 373-8.
    CrossrefPubMedGoogle Scholar
  • 43 Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M. et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia.. J Neurol Neurosurg Psychiatry 2008; 79 (10) 1186-9.
    CrossrefPubMedGoogle Scholar
  • 44 Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H. et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1 A in sporadic inclusion body myositis versus known autoimmune diseases.. Ann Rheum Dis 2016; 75 (04) 696-701.
    CrossrefPubMedGoogle Scholar